Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on cancer treatment using its proprietary phospholipid ether drug conjugate (PDC) platform. Its lead products include iopofosine I 131 (iodine-131 beta-emitter studied in Waldenstrom macroglobulinemia, multiple myeloma, and CNS lymphoma), CLR 125 (iodine-125 Auger-emitter in triple-negative breast cancer), and CLR 225 (actinium-225 alpha-emitter in solid tumors). The company develops phospholipid radioconjugates designed to deliver radioisotopes directly to cancer cells while limiting healthy tissue exposure.
expected 2026-11-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-04 | 2025-12-31 | 0001104659-26-023167 | EDGAR | 73K words |
| 2025-03-13 | 2024-12-31 | 0001410578-25-000329 | EDGAR | 69K words |
| 2024-03-27 | 2023-12-31 | 0001410578-24-000307 | EDGAR | 58K words |
| 2023-03-09 | 2022-12-31 | 0001410578-23-000224 | EDGAR | 57K words |
| 2022-03-21 | 2021-12-31 | 0001410578-22-000436 | EDGAR | — |
| 2021-03-02 | 2020-12-31 | 0001104659-21-030445 | EDGAR | — |
| 2020-03-09 | 2019-12-31 | 0001104659-20-030742 | EDGAR | — |
| 2019-02-26 | 2018-12-31 | 0001144204-19-009973 | EDGAR | — |
| 2018-03-21 | 2017-12-31 | 0001144204-18-016175 | EDGAR | — |
| 2017-03-15 | 2016-12-31 | 0001144204-17-014611 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-13 | 2026-06-30 | 0001104659-26-095426 | EDGAR | 24K words |
| 2025-11-13 | 2025-09-30 | 0001104659-25-110827 | EDGAR | 24K words |
| 2025-08-14 | 2025-06-30 | 0001410578-25-001778 | EDGAR | 24K words |
| 2025-05-13 | 2025-03-31 | 0001410578-25-001205 | EDGAR | 22K words |
| 2024-11-18 | 2024-09-30 | 0001410578-24-002012 | EDGAR | 23K words |
| 2024-10-29 | 2024-06-30 | 0001410578-24-001708 | EDGAR | 22K words |
| 2024-05-14 | 2024-03-31 | 0001410578-24-000771 | EDGAR | 19K words |
| 2023-11-13 | 2023-09-30 | 0001410578-23-002341 | EDGAR | 19K words |
| 2023-08-14 | 2023-06-30 | 0001410578-23-001833 | EDGAR | 16K words |
| 2023-05-04 | 2023-03-31 | 0001410578-23-000875 | EDGAR | 16K words |
| 2022-11-03 | 2022-09-30 | 0001410578-22-002920 | EDGAR | 18K words |
| 2022-08-05 | 2022-06-30 | 0001410578-22-002052 | EDGAR | 17K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-13 | 0001104659-26-095460 | EDGAR | 3K words |
| 2026-03-04 | 0001104659-26-023169 | EDGAR | 3K words |
| 2025-11-13 | 0001104659-25-110848 | EDGAR | 3K words |
| 2025-10-10 | 0001104659-25-098725 | EDGAR | 10K words |
| 2025-10-06 | 0001104659-25-096928 | EDGAR | 2K words |
| 2025-08-14 | 0001104659-25-078102 | EDGAR | 3K words |
| 2025-06-26 | 0001104659-25-062837 | EDGAR | 2K words |
| 2025-06-25 | 0001104659-25-062639 | EDGAR | 1K words |
| 2025-06-18 | 0001104659-25-060661 | EDGAR | 1K words |
| 2025-06-13 | 0001104659-25-059400 | EDGAR | 1K words |
515 total filings indexed. 483 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001279704 |
| Ticker | CLRB |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.cellectar.com |
| Listed | 2005-04-19 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/CLRB (~200 tokens, structured JSON with cryptographic provenance)